Gossamer Bio Faces Delisting Concerns
Ticker: GOSS · Form: 8-K · Filed: 2026-04-09T16:01:13-04:00
Sentiment: bearish
Topics: delisting, compliance, regulatory-issue
Related Tickers: GOSS
TL;DR
GOSS might get delisted - big trouble ahead.
AI Summary
Gossamer Bio, Inc. filed an 8-K on April 9, 2026, to report a notice of delisting or failure to satisfy a continued listing rule or standard, as of April 8, 2026. This indicates potential issues with the company's compliance with stock exchange listing requirements.
Why It Matters
This filing signals potential financial distress or non-compliance, which could lead to the stock being removed from its exchange, impacting liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Gossamer Bio, Inc. (company) — Filer of the 8-K report
- 0001728117 (company) — CIK number for Gossamer Bio, Inc.
- 2026-04-09 (date) — Filing date of the 8-K
- 2026-04-08 (date) — Period of report for the delisting notice
FAQ
What specific listing rule or standard has Gossamer Bio, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Gossamer Bio, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the effective date of the delisting notice?
The period of report for the delisting notice is April 8, 2026.
What actions, if any, does Gossamer Bio, Inc. plan to take to address the delisting concerns?
The provided filing details do not include information on any specific actions Gossamer Bio, Inc. plans to take to address the delisting concerns.
Which stock exchange is Gossamer Bio, Inc. listed on?
The filing does not explicitly state the stock exchange, but the context of a 'continued listing rule or standard' implies it is listed on a major exchange.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 9, 2026, at 16:01:13.
From the Filing
EDGAR Filing Documents for 0001728117-26-000022 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001728117-26-000022 Filing Date 2026-04-09 Accepted 2026-04-09 16:01:13 Documents 11 Period of Report 2026-04-08 Items Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interactive Data Document Format Files Seq Description Document Type Size 1 8-K goss-20260408.htm iXBRL 8-K 30561 Complete submission text file 0001728117-26-000022.txt 144992 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT goss-20260408.xsd EX-101.SCH 1794 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT goss-20260408_lab.xml EX-101.LAB 21629 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT goss-20260408_pre.xml EX-101.PRE 12516 14 EXTRACTED XBRL INSTANCE DOCUMENT goss-20260408_htm.xml XML 2724 Mailing Address 3115 MERRYFIELD ROW SUITE 120 SAN DIEGO CA 92121 Business Address 3115 MERRYFIELD ROW SUITE 120 SAN DIEGO CA 92121 (858) 684-1300 Gossamer Bio, Inc. (Filer) CIK : 0001728117 (see all company filings) EIN. : 475461709 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38796 | Film No.: 26851519 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)